Clinical trial
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
NCT00358449 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00358449 |
|---|---|
| Title | Intravenous Mepolizumab In Children With Eosinophilic Esophagitis |
| Official title | A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Oesophagitis, Eosinophilic |
| Intervention type | Drug |
| Interventions | mepolizumab |
| Enrollment | 84 |
| Start date | Sep 11, 2006 |
| Primary completion | Nov 25, 2008 |
| Completion | Nov 25, 2008 |
| First posted | Jul 31, 2006 |
| Last update posted | Jul 24, 2018 |
| Countries | Australia, Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: